Zobrazeno 1 - 10
of 234
pro vyhledávání: ''
Autor:
Alissa Visram, Francis K. Buadi, Wilson I. Gonsalves, S. Vincent Rajkumar, Angela Dispenzieri, Martha Q. Lacy, Rahma Warsame, Morie A. Gertz, Eli Muchtar, Shaji Kumar, Robert A. Kyle, Nelson Leung, David Dingli, Linda B. Baughn, Suzanne R. Hayman, Prashant Kapoor, Taxiarchis Kourelis
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 11, Pp 1-8 (2021)
Blood Cancer Journal
Blood Cancer Journal
The Mayo-2018 smoldering multiple myeloma (SMM) risk score is used routinely in the clinical setting but has only been validated at diagnosis. In SMM patients, the progression risk decreases over time. However, the utility of applying risk stratifica
Autor:
Mark-David Levin, Paula F. Ypma, Sonja Zweegman, Monique C. Minnema, Pieter Sonneveld, Esther G. M. de Waal, Eduardus F. M. Posthuma, Mirian Brink, Kaz Groen, Niels W.C.J. van de Donk, Ellen van der Spek, Avinash G Dinmohamed, Annemiek Broijl
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 11, Pp 1-7 (2021)
Blood Cancer Journal, 11(11):178. Nature Publishing Group
Blood Cancer Journal
Brink, M, Groen, K, Sonneveld, P, Minnema, M C, Broijl, A, Dinmohamed, A G, van der Spek, E, Levin, M D, Ypma, P F, de Waal, E, Posthuma, E F M W, Zweegman, S & van de Donk, N W C J 2021, ' Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands : a population-based study ', Blood cancer journal, vol. 11, no. 11, 178 . https://doi.org/10.1038/s41408-021-00571-8
Blood cancer journal, 11(11):178. Nature Publishing Group
Blood Cancer Journal, 11(11):178. Nature Publishing Group
Blood Cancer Journal
Brink, M, Groen, K, Sonneveld, P, Minnema, M C, Broijl, A, Dinmohamed, A G, van der Spek, E, Levin, M D, Ypma, P F, de Waal, E, Posthuma, E F M W, Zweegman, S & van de Donk, N W C J 2021, ' Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands : a population-based study ', Blood cancer journal, vol. 11, no. 11, 178 . https://doi.org/10.1038/s41408-021-00571-8
Blood cancer journal, 11(11):178. Nature Publishing Group
Identification of risk factors for early mortality (EM) in multiple myeloma (MM) patients may contribute to different therapeutic approaches in patients at risk for EM. This population-based study aimed to assess trends in EM and risk factors for EM
Autor:
Eli Muchtar, Prashant Kapoor, Lisa Hwa, David Dingli, Taxiarchis Kourelis, Amie Fonder, Morie A. Gertz, Matthew Ho, Shaji Kumar, Suzanne R. Hayman, Saurabh Zanwar, Francis K. Baudi, Nelson Leung, Robert A. Kyle, Miriam Hobbs, Martha Q. Lacy, Angela Dispenzieri, Rahma Warsame, S. Vincent Rajkumar
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-10 (2021)
Blood Cancer Journal
Blood Cancer Journal
The optimal duration of lenalidomide maintenance post-autologous stem cell transplant (ASCT) in Multiple Myeloma (MM), and choice of therapy at relapse post-maintenance, need further evaluation. This retrospective study assessed outcomes of patients
Autor:
Betsy LaPlant, Thomas M. Habermann, Ivana N. Micallef, Luis F. Porrata, Rebecca L. King, Yucai Wang, Stephen M. Ansell, William R. Macon, Patrick B. Johnston, David J. Inwards, Thomas E. Witzig, Sanjal Desai, Grzegorz S. Nowakowski
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-7 (2021)
Blood Cancer Journal
Blood Cancer Journal
Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL. Herein we present an analysis of
Autor:
Xinxin Cao, Jun Feng, Lu Zhang, Yan-ying Yu, Hao Zhao, Xue-min Gao, Daobin Zhou, Hao Cai, Jian Li
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 8, Pp 1-5 (2021)
Blood Cancer Journal
Blood Cancer Journal
Autor:
Vishal Bhatnagar, Laura L. Fernandes, Paul G. Kluetz, Jiaxi Zhou, Thomas Gwise, Erica G. Horodniceanu, Bindu Kanapuru
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 8, Pp 1-6 (2021)
Blood Cancer Journal
Blood Cancer Journal
Over the past 13 years, there have been advances in characterizing the patient experience in oncology trials, primarily using patient-reported outcomes (PROs). This review aims to provide details on the PRO measures and analyses used in multiple myel
Autor:
Yucai Wang, Arushi Khurana, Thomas M. Habermann, Jose C. Villasboas, Brian K. Link, William R. Macon, Stephen M. Ansell, Matthew J. Maurer, Raphael Mwangi, James R. Cerhan, Rebecca L. King, Christopher Strouse, Grzegorz S. Nowakowski, Thomas E. Witzig
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-6 (2021)
Blood Cancer Journal
Blood Cancer Journal
Immediate treatment for asymptomatic, low-tumor burden follicular lymphoma (FL) has not shown an overall survival benefit over “watch and wait” (W/W) strategy. We estimated incidence of treatment initiation at specific time points and assessed it
Autor:
Jia-Ying Wu, Yi Xiao, Yicheng Zhang, Jianfeng Zhou, Fankai Meng, Yang Cao, Na Wang, Xiaojian Zhu, Jue Wang, Lifang Huang
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-8 (2021)
Blood Cancer Journal
Blood Cancer Journal
Chimeric antigen receptor (CAR) T-cell immunotherapy following autologous stem cell transplantation (ASCT) is a promising method for refractory or relapsed multiple myeloma, but explicit data for central nervous system lymphoma (CNSL) are lacking. He
Autor:
Peter Májek, Ruochen Jia, Michael Schuster, Leon Kutzner, Anna Koren, André C. Müller, Joanna I. Loizou, Robert Kralovics, Christoph Bock, Stefan Kubicek, Kathrin Runggatscher
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-10 (2021)
Blood Cancer Journal
Blood Cancer Journal
Mutations of calreticulin (CALR) are the second most prevalent driver mutations in essential thrombocythemia and primary myelofibrosis. To identify potential targeted therapies for CALR mutated myeloproliferative neoplasms, we searched for small mole
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 6, Pp 1-9 (2021)
Blood Cancer Journal
Blood Cancer Journal
In 1957, Hillestad et al. defined acute promyelocytic leukemia (APL) for the first time in the literature as a distinct type of acute myeloid leukemia (AML) with a “rapid downhill course” characterized with a severe bleeding tendency. APL, accoun